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Increasing the success rate of rotator cuff healing remains tremendous challenge. Among many approaches, the possibility of
activating resident stem cells in situ, without the need to isolate them from biopsies, could represent valuable therapeutic strategy.
Along this line, it has been recently demonstrated that lipoaspirate product, Lipogems, contains and produces growth-factors
that may activate resident stem cells. In this study, human tendon stem cells (hTSCs) from the rotator cuff were cocultured in a
transwell system with the Lipogems lipoaspirate product and compared to control untreated cells in terms of cell proliferation,
morphology, stem cell marker and VEGF expression, and differentiation and migration capabilities. Results showed that the
Lipogems product significantly increases the proliferation rate of hTSCs without altering their stemness and differentiation
capability. Moreover, treated cells increase the expression of VEGF, which is crucial for the neovascularization of the tissue during
the healing process. Overall, this study supports that directly activating hTSCs with the Lipogems lipoaspirate could represent a
new practical therapeutic approach. In fact, obtaining a lipoaspirate is easier, safer, and more cost-effective than harvesting cells
from tendon or bone marrow biopsies, expanding them in GMP facility and then reinjecting them in the patient.
1. Introduction
Rotator cuff tears represent the vast majority of shoulder
injuries in adult patients and are a common contributing
factor to shoulder pain and occupational disability, whose
prevalence is rising due to the increase of the world popu-
lation age [1]. Although surgical procedures for rotator cuff
repair have evolved and improved over the past decades,
a high rate of retear is still observed [2–4]. This is mainly
caused by a failure of tendon healing, especially in the case
of the supraspinatus tendon [5–9]. Therefore, increasing the
success rate of rotator cuff healing remains a tremendous
challenge for orthopedic surgeons, which encourages the
development of new alternative therapies [10–15]. In fact,
once injured, tendons do not completely regain the normal
structural and biomechanical properties, resulting in the
formation of scar tissue, adhesions, fatty infiltration, and
matrix disorganization, which increase the risk of retear.
Among several factors, tendon poor vascularization reduces
the availability of oxygen, growth-factors, and other nutrients
necessary for tissue regeneration and significantly affects the
quality and speed of the tendon healing response. Therefore,
in considering new strategies for tendon engineering, the
goal of promoting neoangiogenesis is vital to accelerate
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the healing process. Moreover, several studies have shown
that different types of stimuli could activate the nor-
mal growth-factor-mediated healing cascades [16]. Along
this line, it has been recently demonstrated that lipoaspi-
rates contain and produce growth-factors, such as platelet-
derived growth-factor (PDGF), fibroblast growth-factor
(FGF), transforming growth-factor beta (TGF-𝛽), and vas-
cular endothelial growth-factor (VEGF), which are known to
play important regulatory roles in cellular functions, includ-
ing adhesion, chemotaxis, proliferation, migration, matrix
synthesis, differentiation, and angiogenesis [16–18]. The cell
fraction responsible for growth-factor production and regu-
lation is mainly the stromal vascular fraction, which could
have acceleratory effect on the healing process of injured
tendons [19]. Given the tissue availability, as well as the
easy and minimally invasive access to tissue sources, adipose
tissue may in fact represent a potential choice for tendon
repair and regeneration [20]. Among many approaches, an
innovative technology, Lipogems, provides a nonexpanded,
ready-to-use, and microfragmented adipose tissue that is
expected to have the peculiar advantage of maintaining an
intact stromal vascular niche harboring cellular elements
with mesenchymal stem cell and pericyte characteristics [21].
This system works through a mild mechanical tissue cluster-
size reduction in a completely closed system, avoiding the use
of any enzyme, additives, and other additional manipulations
(i.e., centrifugation and subfractional harvesting) [21].
In a previous study on the Lipogems product, Bianchi
et al. speculated that the action of the Lipogems product, due
to an intact stromal vascular niche, could involve the secre-
tion of trophic mediators delivering instructive messages
that functionally promote a more compliant regenerative
environment within the recipient tissue [21]. In particular,
the lipoaspirate could stimulate the self-healing processes
by activating resident stem cells through paracrine mecha-
nisms.Therefore, the Lipogems product may be instrumental
for activating resident progenitor cells to proliferate and
contribute to the tendon healing process. Actually, it has
been recently demonstrated that also the human rotator
cuff contains a reservoir of progenitor cells, which can be
isolated and expanded in vitro [22–26]. Thus, the availability
of a completely closed disposable system for adipose tissue
processing could allow the procedure to be readily, safely,
and economically performed in clinical settings to afford
significant tissue repair, overcoming the difficulty of an ex
vivo expansion and the complexity of the current Good
Manufacturing Practice (GMP) requirements for preparing
cells for a therapeutic use [27].
On these bases, the aim of this study was to assess
the effects of the Lipogems product on primary cultures of
human tendon stem cells (hTSCs).
2. Materials and Methods
2.1. Cell Cultures. Human tendon stem cells (hTSCs) were
isolated from supraspinatus tendon specimens collected
during arthroscopic rotator cuff repair, according to our
previous procedure [22]. The isolated hTSCs were cul-
tured in normal growth medium composed of 𝛼-Minimal
Essential Medium (𝛼-MEM) (Sigma-Aldrich) supplemented
with 2mM glutamine (Euroclone), 1% antibiotic-antimycotic
mixture (Euroclone), and 20% (v/v) fetal bovine serum (FBS)
(HyClone, Thermo Fisher Scientific) at 37∘C in a humidified
atmosphere of 5% CO
2
. The medium was changed every 2-3
days. All experiments were carried out with cells at passage
four after isolation.
2.2. Processing of Adipose Tissue with the Lipogems Device.
Human subcutaneous adipose tissue samples were obtained
with patient informed consent from abdominal lipoaspira-
tion procedures performed before arthroscopic rotator cuff
repair and processed by using the Lipogems device, according
to the manufacturer’s instructions previously described [21].
Avoiding the presence of air, the lipoaspirate tissue was
subjected to a first cluster reduction, obtained by pushing
the lipoaspirate from the syringe into the device through the
first large filter (blue cap), and allowing the corresponding
quantity of saline to exit towards the wasting bag. The five
stainless steel beads contained in the device were essential to
obtain a temporary emulsion between oil, blood, and saline,
which could be washed away against density following the
current of saline moved by gravity in the wasting bag. After
this washing step (the flowing solution appears clear and
the lipoaspirate yellow), the saline flux was stopped and the
device was reversed (gray cap up), leading to the second
adipose cluster reduction. Such reduction was obtained by
pushing the floating adipose clusters through the second
cutting hexagonal filter (grey cap), pushing fluid from below
with a 60mL syringe. The reduced cluster was collected in
another 60mL syringe placed above and positioned to gently
decant the Lipogems product by gravity in order to remove
excessive saline solution. Amean of 50mL of lipoaspirate was
collected and processed with the Lipogems device to obtain
an amount of 20mL of the final Lipogems product, whichwas
transferred to several 10mL syringes to be reinjected in the
same patient or used in our experiments.
2.3. Lipogems Coculture Experiments of hTSCs with the
Lipogems Product. hTSCs were seeded on the bottom of 6-
well plates in normal growth medium. Twenty-four hours
after seeding, a volume of 250 𝜇L of the freshly processed
Lipogems product was transferred to the transwell polycar-
bonate microporous inserts (0.4𝜇m membrane pore size,
Falcon BD, Figure 1) above hTSCs monolayers, allowing for
potential diffusion of soluble mediators but preventing cell-
cell contact. Control cells were cultured under the same
conditions without the Lipogems product. The medium was
replaced every 48 h in all experiments. To study the effects
of the Lipogems treatment on multilineage differentiation
potential of hTSCs, cells were cultured with the Lipogems
product in osteogenic and adipogenic differentiation media,
as described below.
2.4. Cell Morphology and Proliferation. For analysis of cell
viability, hTSCs were plated at a concentration of 2.6 × 103
cells/cm2 and exposed to the Lipogems product for 96 h,
as described above. Cell morphology was examined daily
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Figure 1: Schematic illustration of the Lipogems device and the transwell coculture system of hTSCs with the Lipogems product. The
lipoaspirate was processed using the Lipogems device to obtain the final Lipogems product. A transwell coculture systemwas used to study the
effects of the Lipogems product on primary cultures of hTSCs. Cells were seeded on the bottom of a 6-well plate in normal growth medium.
Twenty-four hours after plating, the Lipogems product was transferred in the upper well of a transwell cell culture system (250𝜇L/transwell
insert), separated from hTSCs in the lower well by a 0.4 𝜇m microporous polycarbonate membrane. hTSCs and Lipogems product were
maintained in coculture for successive analyses.
with a phase-contrast microscope (Axiovert 40 CFL, Zeiss,
equipped with a Moticam 2300 camera, Motic) to assess the
effects of the Lipogems product on hTSCs phenotype. Cell
growth curves were prepared by harvesting with Trypsin-
EDTA solution (Sigma-Aldrich) and then counting with
a Countess Cell Counter (Invitrogen, Life Technologies),
according to the manufacturer’s procedure. Cell viability was
determined by trypan blue dye exclusion assay. All assays
were carried out in triplicate for each sample.
2.5. Cell Apoptosis. Apoptosis was measured by flow cytome-
try on Lipogems-treated and control cells at 0, 48, and 96 h
of treatment using Annexin V-FITC Apoptosis Detection
Kit (Enzo Life Sciences), according to the manufacturer’s
protocol. Briefly, adherent cells were trypsinized, washed
in PBS by gentle shaking, and resuspended with 200 𝜇L of
a specific Binding Buffer (10mM HEPES/NaOH, pH 7.4;
140mMNaCl; 2.5mMCaCl
2
) containing 5𝜇L of Annexin V-
FITC. After incubation for 10min in the dark at room tem-
perature, cells were washed in PBS, resuspended in 200𝜇L of
Binding Buffer, and then stainedwith 10𝜇LPropidium Iodide
(20𝜇g/mL). Samples were acquired with a Navios Flow
Cytometer (Beckman Coulter) and analyzed using Kaluza 1.2
software (Beckman Coulter).
2.6. Flow Cytometric Analysis. After a four-day treatment,
Lipogems-treated and control cells were characterized
by flow cytometry for the expression of key stem cell
markers. Flow cytometry analysis was performed on 1 × 105
cells/sample. Briefly, aspecific binding sites were blocked
with a blocking solution (50% 1x PBS, 50% FBS) for 30min
at room temperature and washed twice with PBS at 4∘C.
Cells were stained with fluorochrome-conjugated mouse
antihuman antibodies at the optimal concentration (1 : 20
dilution) in PBS for 10min at 4∘C and washed twice with
PBS at 4∘C. Cell characterization was performed using
the following antibodies: 𝛼CD9 FITC, 𝛼CD73 FITC,
𝛼HLA-DR FITC, 𝛼CD13 PE, 𝛼CD29 PE, 𝛼CD44 PE,
𝛼CD45 PE, 𝛼CD71 PE, 𝛼CD90 PE, 𝛼CD105 PE, 𝛼CD106
PE, 𝛼CD34 PerCP-eFluor710, 𝛼CD166 PerCP-eFluor710,
𝛼HLA-ABC FITC, 𝛼NG2 PE, and 𝛼SSEA-4 PE (all from
eBioscience); 𝛼Lineage Cocktail FITC, 𝛼CD18 PE, 𝛼CD140a
PE, 𝛼CD140b APC, 𝛼CD146 PE, and 𝛼Stro-1 Alexa Fluor 647
(all from BioLegend); and 𝛼CD117 PE (Miltenyi Biotec). The
respective isotype antibodies were used as controls. Samples
were acquired with a Navios Flow Cytometer (Beckman
Coulter) and data were processed with Kaluza software
(Beckman Coulter).
2.7. Adipogenic Differentiation. To assess the effects of the
Lipogems product on the adipogenic differentiation capacity
of hTSCs, cells were plated at a concentration of 3 × 104
cells/cm2 and preconditioned with the Lipogems product
for 96 h in normal growth medium and then switched to
DMEM-low glucose (Sigma-Aldrich), 10% FBS (HyClone,
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Thermo Fisher Scientific), 4mM L-glutamine (Euroclone),
and 1% antibiotic-antimycotic mixture (Euroclone), with
the addition of the mesenchymal stem cell adipogenesis
kit (Millipore) for 21 days, according to the manufacturer’s
instructions. At day 21, Oil Red O solution (Millipore) was
used to stain lipid droplets of derived adipocytes, according
to themanufacturer’s procedures. All photomicrographswere
acquired with Axiovert 40 microscope (Zeiss) equipped with
a Moticam 2300 camera (Motic). The adipogenic medium
was changed every 2-3 days.
2.8. Osteogenic Differentiation. To assess the effects of the
Lipogems product on the osteogenic differentiation capacity
of hTSCs, cells were plated at a concentration of 3 × 104
cells/cm2 and preconditioned with the Lipogems product
for 96 h in normal growth medium and then switched
to the osteogenesis induction medium, which was con-
stituted of DMEM-low glucose (Sigma-Aldrich), 10% FBS
(HyClone, Thermo Fisher Scientific), 4mM L-glutamine
(Euroclone), and 1% antibiotic-antimycotic mixture (Euro-
clone), supplemented with 0.1𝜇Mdexamethasone, 50 𝜇g/mL
L-ascorbic acid-2-phosphate, and 10mM𝛽-glycerophosphate
(all reagents from Sigma-Aldrich) for 17 days. At day 17,
Alizarin Red solution (Millipore) was used to detect calcium
deposition in derived osteoblasts according to the manufac-
turer’s instruction. All photomicrographs were acquired with
Axiovert 40 microscope (Zeiss) equipped with a Moticam
2300 camera (Motic). The osteogenic medium was changed
every 2-3 days.
2.9. RNA Extraction and Real-Time PCR. Total RNA was
isolated using TRIzol Reagent (Ambion, Life Technologies),
and 1 𝜇g of extracted RNA was reverse transcribed to cDNA
using the iScript cDNA synthesis kit (BioRad) according to
the manufacturer’s instructions. Real-Time PCR was per-
formed in a 96-well plate with 10 ng of cDNA as template,
0.2 𝜇M primers, and 1x Power SYBR Green PCR Master
Mix (Applied Biosystems, Life Technologies) in 20𝜇L final
volume per well using a StepOnePlus Real-Time PCR System
(Applied Biosystems). The mRNA levels of Tenomodulin
(TNMD), collagen type I alpha-1 (COL1A1), Tenascin C,
Nanog homeobox (Nanog), octamer-binding transcription
factor 4 (Oct4), kruppel-like factor 4 (KLF4), vascular
endothelial growth-factor (VEGF), peroxisome proliferator-
activated receptor-𝛾 (PPAR-𝛾), lipoprotein lipase (LPL), alka-
line phosphatase (ALP), myogenin (MYOG), and myogenic
differentiation 1 (MYOD) were assessed. Ribosomal pro-
tein S14 (S14) was used as reference gene in quantitative
analysis. We performed a series of validation experiments
confirming that S14 is constitutively and stably expressed
in all cell samples, with an amplification efficiency of 97.8%
and linear response in the expression range studied (Supple-
mentary Figure 1 in Supplementary Material available online
at http://dx.doi.org/10.1155/2016/4373410). Primer sequences
are as follows: TNMD, forward 5󸀠-TGTATTGGATCAATC-
CCACTCTAAT-3󸀠 and reverse 5󸀠-TTTTTCGTTGGCAGG-
AAAGT-3󸀠; COL1A1, forward 5󸀠-GGGATTCCCTGGACC-
TAAAG-3󸀠 and reverse 5󸀠-GGAACACCTCGCTCTCCA-3󸀠;
Tenascin C, forward 5󸀠-CGGGGCTATAGAACACCAGT-
3󸀠 and reverse 5󸀠-AACATTTAAGTTTCCAATTTCAGG-
TT-3󸀠; Nanog, forward 5󸀠-GGTCCCAGTCAAGAAACA-
GA-3󸀠 and reverse 5󸀠-GAGGTTCAGGATGTTGGAGA-3󸀠;
Oct4, forward 5󸀠-AGGAGAAGCTGGAGCAAAA-3󸀠 and
reverse 5󸀠-GGTCGAATACCTTCCCAAA-3󸀠; KLF4, for-
ward 5󸀠-GACTTCCCCCAGTGCTTC-3󸀠 and reverse 5󸀠-
CGTTGAACTCCTCGGTCTC-3󸀠; VEGF, forward 5󸀠-CAA-
CATCACCATGCAGATTATGC-3󸀠 and reverse 5󸀠-TCG-
GCTTGTCACATTTTTCTTGT-3󸀠; PPAR-𝛾, forward 5󸀠-
TTCCTTCACTGATACACTGTCTGC-3󸀠 and reverse 5󸀠-
GGAGTGGGAGTGGTCTTCCATTAC-3󸀠; LPL, forward
5󸀠-AGAGAGAACCAGACTCCAATG-3󸀠 and reverse 5󸀠-
GGCTCCAAGGCTGTATCC-3󸀠; ALP, forward 5󸀠-CGC-
ACGGAACTCCTGACC-3󸀠 and reverse 5󸀠-GCCACCACC-
ACCATCTCG-3󸀠;MYOG, forward 5󸀠-AAGAAGGGGAGA-
GGAACAGC-3󸀠 and reverse 5󸀠-GCAACTTCAGCACAG-
GAGAC-3󸀠; MYOD, forward 5󸀠-GCTAGGTTCAGCTTT-
CTCGC-3󸀠 and reverse 5󸀠-CACCTGCTACATTTGGGACC-
3󸀠; and S14, forward 5󸀠-GTGTGACTGGTGGGATGAAGG-
3󸀠 and reverse 5󸀠-TTGATGTGTAGGGCGGTGATAC-3󸀠.
Amplification Protocol. An initial denaturation at 95∘C for
3min, followed by 40 cycles of 5 s each at 95∘C and 30 s at
57∘C. Relative quantification of target genes was performed in
triplicate, analyzed using the 2−ΔΔCt method, and normalized
to the corresponding S14 values.
2.10. Cell Migration by Wound-Healing Assay. Wound-
healing assay was performed as previously described [28].
hTSCs were grown to confluence in 6-well plates and treated
with the Lipogems product or cultured in the growthmedium
alone. A sterile P200 pipet tip was used to create a scratch
across the cell monolayer. Then, cultures were washed once
with 1mL of growth medium to remove the damaged and
detached cells. After replacing the medium, hTSCs were
allowed to grow for 48 h. At different time points, cell cultures
were examined with a phase-contrast microscope (Axiovert
40 CFL, Zeiss, equippedwith aMoticam 2300 camera,Motic)
and images of the same scratch fields were acquired at time
0 and after 17, 20, 25, 30, and 42 h from the scratch. The
gap area between the cells was calculated in each acquired
image using software ImageJ. The migration rate was based
on the measure of the recovered wound area (experimental
data expressed in percentage). All assays were carried out in
triplicate for each sample.
2.11. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism v 6.0 software (GraphPad Software
Inc.). Data were typical results from three replicate experi-
ments for each of the three patients-derived cell lines and
were expressed as mean ± standard deviation (SD). Paired
comparisons were performed by two-tailed 𝑡-test. The signif-
icance level was set at 𝑝 value lower than 0.05.
3. Results
To assess the effects of the Lipogems product on hTSCs,
cells were cocultured for up to 96 h with freshly obtained
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Figure 2: Effects of the Lipogems product on hTSCs morphology and proliferation. (a) Phase-contrast microphotographs (original
magnification ×10) and (b) cell growth curves of hTSCs during 96 h treatment with the Lipogems product in normal growth medium and
compared to control cells. All experiments were performed in triplicate. Error bars show the mean ± SD of three different experiments. 𝑝
values were calculated using Student’s 𝑡-test. Only 𝑝 values < 0.05 are indicated: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01, as compared to control cells.
Lipogems product in a transwell cell culture system as
described in the Methods and graphically outlined in
Figure 1. Control hTSCs were cultured using the same tran-
swell system, but without adding the Lipogems product.
3.1. Effects on Cell Morphology and Proliferation. Cell mor-
phology analysis revealed no significant differences between
Lipogems-treated and control cells during 96 h treatment
(Figure 2(a), cell morphology at 48 h after treatment). Cell
growth analysis revealed a statistically significant increase in
cell proliferation of Lipogems-treated cells as compared to
controls, the effect being statistically significant after 48 h. In
particular, hTSCs showed a significant increase of 24% (𝑝 <
0.01), 9.7% (𝑝 < 0.05), and 5% (𝑝 < 0.01) in the presence
of the Lipogems product at 48, 72, and 96 h, respectively, as
compared to control cells (Figure 2(b)).
3.2. Effects on Cell Apoptosis. Apoptosis was measured by
flow cytometry on hTSCs at 0, 48, and 96 h of treatment with
the Lipogems product using Annexin V-FITC and compared
to control cells at the same time points (Figure 3). Results
revealed no significant apoptosis in all tested samples (always
below 0.5%), with no significant differences between control
and Lipogems-treated cells.
3.3. Effects on Cell Phenotype by Flow Cytometry. The expres-
sion of key stem cell markers was evaluated by flow cytom-
etry in hTSCs after a 96 h treatment with the Lipogems
product and compared to control untreated cells. Results of
comparative flow cytometry analyses showed no significant
differences between the two groups for all tested markers
(Table 1).
3.4. Effects on Tenogenic, Adipogenic, Osteogenic, and
Myogenic Differentiation Promotion. We assessed whether
Lipogems product treatment would induce hTSCs to
differentiate into other cell phenotypes. We found that 96 h
exposure to Lipogems product did not increase nor induce
the expression of mRNA levels of tenogenic (Tenomodulin,
COL1A1, Tenascin C) (Figure 4(a)), adipogenic (PPAR-𝛾 and
LPL), osteogenic (ALP), and myogenic (MYOD, MYOG)
markers (Supplementary Figure 2).
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Figure 3: Effects of the Lipogems product on hTSCs apoptosis. Flow cytometric analysis of hTSCs survival rate at 0, 48, and 96 h after the
treatmentwith the Lipogems product (right panel) as compared to control cells (left panel), throughdouble stainingwithAnnexinV-FITCand
PI. Early apoptotic cells (Annexin V-positive/PI-negative) are localized in the lower right region, late apoptotic and necrotic cells (Annexin
V-positive/PI-positive) are localized in the upper regions, and vital cells (double negative) are localized in the lower left region.
3.5. Effects on Cell Plasticity. To assess the effects of the
Lipogems product on the multidifferentiation capacity of
hTSCs, cells preconditioned with the Lipogems product for
96 h were induced to differentiate in vitro toward adipocytes
and osteoblasts Figures 4(b) and 4(c); see Methods.
Results showed no noticeable differences in the adipogenic
(Figure 4(b)) and osteogenic (Figure 4(c)) differentiation
of hTSCs, suggesting no significant effects of Lipogems
treatment on the differentiation capacity towards these cell
phenotypes.
Stem Cells International 7
TNMD
hTSCs (control)
COL1A1
0.5
1.0
0.0
Tenascin C
N/E N/ERQ
0.5
1.5
1.0
0.0
RQ
0.5
1.5
1.0
0.0
RQ
hTSCs + LipogemshTSCs (control) hTSCs + Lipogems
hTSCs (control) hTSCs + Lipogems
(a) Tendon marker expression
hTSCs + AM+LipogemshTSCs (control) + AM
AM = adipogenic medium
(b) Adipogenic differentiation
hTSCs + OM+LipogemshTSCs (control) + OM
OM = osteogenic medium
(c) Osteogenic differentiation
0.5
1.5
1.0
0.0
RQ
0.5
1.5
1.0
0.0
RQ
0.5
1.5
1.0
0.0
RQ
Nanog Oct4
KLF4
hTSCs (control) hTSCs + Lipogems hTSCs (control) hTSCs + Lipogems
hTSCs (control) hTSCs + Lipogems
(d) Stem cell marker expression
0.5
1.5
1.0
0.0
RQ
hTSCs (control) hTSCs + Lipogems
VEGF
∗∗
(e) VEGF expression
Figure 4: Continued.
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Figure 4: Effects of the Lipogems product on tendon marker expression. (a) Gene expression of TNMD, Tenascin C, and COL1A1 by Real-
Time PCR at 96 h of treatment with the Lipogems product. Values are expressed as fold-changes relative to control cells. Effects of the
Lipogems product on the in vitro differentiation of hTSCs toward the adipogenic and the osteogenic phenotypes. Adipogenic and osteogenic
differentiation ability of hTSCs cultured with the Lipogems product in the appropriate differentiation medium was evaluated by Oil Red O
(b) and Alizarin Red-S (c) staining, respectively. (b) Lipid intracellular droplets (red) in the adipocytes were stained with Oil Red O solution.
(c) Alizarin Red-S staining revealed the presence of calcium deposits (yellowish-brown). Typical results are shown. Original magnification
×10. Effect of Lipogems treatment on stem cells marker (Nanog, Oct4, and KLF4) (d) and VEGF (e) expression by Real-Time PCR at 96 h of
treatment with the Lipogems product. Values are expressed as fold-changes relative to control cells. Effect of the Lipogems product on hTSCs
migration. (f) Representative time-lapse migration images of control and Lipogems-treated cells. Images were acquired at 0 and 25 h in in
vitro wound-healing assay. Original magnification ×5. The migration rate was measured by quantifying the total area of the wounded region
lacking cells. The average percentages of recovered area obtained from three different experiments at 17, 20, 25, 30, and 42 h of treatment with
the Lipogems product, as compared to control cells. All quantitative data are expressed as the means ± SD of three different experiments. 𝑝
values were calculated using Student’s 𝑡-test. Only 𝑝 values < 0.05 are indicated: ∗∗𝑝 < 0.01, compared to control cells.
3.6. Effects on Stem Cell Marker and VEGF Expression. To
evaluate the effects of Lipogems treatment on hTSCs stem-
ness, the expression of Nanog, Oct4, and KLF4wasmeasured
by Real-Time PCR and compared to that of control untreated
cells (Figure 4(d)). Results revealed no significant differences
in stem cell marker expression between Lipogems-treated
and control cells. Analysis of the VEGF, a key marker
involved in vasculogenesis and angiogenesis, by Real-Time
PCR revealed a significantly higher mRNA expression level,
about 1.3-fold (𝑝 < 0.01) in Lipogems-treated cells as
compared to control cells (Figure 4(e)).
3.7. Effects on Cell Migration. In order to evaluate the effects
of the Lipogems product on the repairing capacity of hTSCs,
an in vitro wound-healing assay was performed. The wound
was completely closed in all conditions within 45–48 h, and
Lipogems-treated and control cells showed a similar rate of
wound closure (a representative image of Lipogems-treated
and control hTSCs moving into the wound space is shown
in (Figure 4) for both groups at 0 and 25 h after scratching).
Quantitative analyses indicated no significant differences in
cellmigration velocity between Lipogems-treated and control
cells at all time points (𝑝 < 0.05, Figure 4(f)).
4. Discussion
The stromal vascular fraction, which is mainly responsible
for growth-factors production and regulation, has been suc-
cessfully used in orthopedic practice [19, 29–31]. However, a
precise chemical identification of these factors is still missing.
Nonetheless, many reports support the notion that a defined
combination of thesemolecules could greatly improve rotator
cuff tendon healing via autocrine and paracrine signaling [16,
17]. For instance, according to the results recently reported by
Doornaert et al., it is likely that the lipoaspirate provides local
signals to stimulate the self-healing processes by activating
resident stem cells through paracrine mechanisms [16]. The
recent discovery that also the human rotator cuff possesses
a population of resident progenitor stem cells [22, 23], that
can be easily isolated and cultured in vitro, allowed the design
of this study, with the ultimate goal of better understanding
the effects of the Lipogems product on adult stem cells. A
key question that needed to be addressed was to ascertain
whether the beneficial effects of the Lipogems product were
due to soluble factors released by the lipoaspirate. Therefore,
the use of a transwell system allowed studying the effects
of Lipogems product without a direct contact between the
lipoaspirate and the stem cell population. These types of
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Table 1: Summary of the surface markers by cytofluorimetry of
Lipogems-treated and control hTSCs. Numbers show the expression
percentage for each cell surface protein.
Markers hTSCs (control) (%) hTSCs + Lipogems (%)
CD9 55.31 65.91
CD13 100 100
CD18 0 0
CD29 98.27 96.77
CD34 0 0
CD44 100 100
CD45 0 0
CD71 62.28 37.25
CD73 100 100
CD90 100 100
CD105 100 100
CD106 3.98 2.30
CD117 0 0
CD140a 0 0
CD140b 47.15 3.46
CD146 1.35 0
CD166 84.72 86.99
HLA-ABC 100 100
HLA-DR 0 0
Lineage 0.23 0
NG2 0 0
SSEA-4 0 0
Stro-1 0 0
indirect coculturing systems have been previously used to
successfully direct the differentiation of stem cells and to
promote cell survival and expansion in vitro [32]. Thus, in
all reported experiments, we could assume that the observed
effects were due to soluble factors released in the medium
by the lipoaspirate. Results showed that hTSCs cocultured
with the Lipogems product significantly increased their
proliferation capability, with no appreciable cytotoxic effects.
Indeed, finding new ways to activate stem cells is vital for
an effective treatment, as stem cell progenitors are usually
present in very low numbers in adult tissues. Attempts to
circumvent the problem by harvesting adult progenitors from
biopsies, expanding them in vitro, and then reinjecting into
the patients have many drawbacks. In fact, isolating and
culturing stem cells at GMP level are very troublesome
and expensive. Moreover, to date, all methods for culturing
stem cells in vitro cannot prevent their tendency to lose
potency during passages and eventually to become senescent.
Therefore, local injection of products like Lipogems could
represent a more practical way of activating resident stem
cells without the need to isolate them from biopsies. Our
results are in agreement with those reported on Human
Umbilical Vein Endothelial Cells (HUVECs), where amarked
proliferation increase by Lipogems product addiction to the
cultures was observed [33]. Interestingly, in our study, we
did not observe any loss of stemness when hTSCs were
cultured in the presence of Lipogems product, as no signif-
icant changes in key stem cells markers could be observed.
Moreover, treatment with Lipogems product alone did not
induce tenogenesis, adipogenesis, osteogenesi, nor myogen-
esis. These findings support the notion that the lipoaspirate
releases factors that increase stem cell proliferation without
altering their potency. These results were confirmed also by
differentiation experiments, where Lipogems-treated hTSCs
could be induced to differentiate towards osteoblasts and
adipocytes with the same efficiency as untreated controls.
Finally, we observed that Lipogems exposure moderately
increases hTSC expression of VEGF, which has been shown
to play a central role in the neovascularization process, being
the main regulator of angiogenesis [17, 34–39]. While at
this stage we cannot predict whether the observed VEGF
increase could have biological effects, angiogenesis is to be
considered an essential factor in designing novel approaches
for tissue engineering, as the restoration of blood flow would
provide a source of nutrients and oxygen and metabolic
substrates and also the access for circulating cells that can
help supporting tissue regeneration [19, 40]. Although no
studies have directly evaluated the role of VEGF in rotator
cuff repair, some reported results demonstrate an improved
tensile strength in animal tendon healing models with VEGF
augmentation [17, 41]. Moreover, increase in VEGF mRNA
expression levels in a rat model of supraspinatus tendon
overuse injury was reported [42]. Clearly, at this stage,
it cannot be excluded that the Lipogems product releases
paracrine angiogenic and antiapoptotic factors other than
VEGF. It has been documented that intact human adipose
stem cells (hASCs), which can be found in the Lipogems
product, are significantlymore responsive than enzymatically
dissociated hASCs to a mixture of hyaluronic, butyric, and
retinoic acid, previously shown to induce stem cell expression
of several vasculogenic genes. Therefore, the peculiarity and
effectiveness of the Lipogems productmay reside in the easily
obtainable source of living hASCs that, once injected, could
release a variety of soluble factors able to activate resident
hTSCs.
5. Conclusions
Herein we reported the effects of the Lipogems lipoaspirate
on human tendon stem cells from the rotator cuff. Coculture
of these progenitor cells with Lipogems released factors sig-
nificantly increases cell proliferation, without affecting stem
cell marker expression and differentiation capability. Overall,
these results support that activating resident progenitor cells
with the Lipogems product, without the need to isolate stem
cells from a biopsy, expanding them in vitro, and then re-
injecting them into the patient, could be a practical and
cost-effective new therapeutic approach for increasing rotator
cuff tendon healing. Although the Lipogems product released
factors have yet to be identified, preliminary results in our
laboratories revealed that the effects are not limited to tendon
stem cells. In fact, preliminary increase in proliferation could
be observed also on stem cells from the cardiovascular system
(data not shown). Therefore, understanding the chemical
composition of the Lipogems product could allow chemical
10 Stem Cells International
synthesis of these factors and using them instead of the
lipoaspirate. Further studies in this direction are currently
ongoing in our laboratories.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
Pietro Randelli andAlessandraMenon equally contributed to
this paper.
References
[1] J. S. Sher, J. W. Uribe, A. Posada, B. J. Murphy, and M. B.
Zlatkin, “Abnormal findings on magnetic resonance images of
asymptomatic shoulders,”The Journal of Bone & Joint Surgery—
American Volume, vol. 77, no. 1, pp. 10–15, 1995.
[2] M. Chen, W. Xu, Q. Dong, Q. Huang, Z. Xie, and Y. Mao,
“Outcomes of single-row versus double-row arthroscopic rota-
tor cuff repair: a systematic review andmeta-analysis of current
evidence,” Arthroscopy, vol. 29, no. 8, pp. 1437–1449, 2013.
[3] Y. G. Rhee, N. S. Cho, and J. H. Yoo, “Clinical outcome and
repair integrity after rotator cuff repair in patients older than 70
years versus patients younger than 70 years,” Arthroscopy, vol.
30, no. 5, pp. 546–554, 2014.
[4] M. D. McElvany, E. McGoldrick, A. O. Gee, M. B. Neradilek,
and F. A. Matsen, “Rotator cuff repair: published evidence on
factors associated with repair integrity and clinical outcome,”
The American Journal of Sports Medicine, vol. 43, no. 2, pp. 491–
500, 2015.
[5] C.-F. Liu, L. Aschbacher-Smith, N. J. Barthelery, N. Dyment,
D. Butler, and C. Wylie, “What we should know before using
tissue engineering techniques to repair injured tendons: a
developmental biology perspective,” Tissue Engineering Part B:
Reviews, vol. 17, no. 3, pp. 165–176, 2011.
[6] R. B. Evans, “Managing the injured tendon: current concepts,”
Journal of HandTherapy, vol. 25, no. 2, pp. 173–190, 2012.
[7] S. Hoppe, M. Alini, L. M. Benneker, S. Milz, P. Boileau, and M.
A. Zumstein, “Tenocytes of chronic rotator cuff tendon tears
can be stimulated by platelet-released growth factors,” Journal
of Shoulder and Elbow Surgery, vol. 22, no. 3, pp. 340–349, 2013.
[8] K. D.Weeks III, J. S. Dines, S. A. Rodeo, and A. Bedi, “The basic
science behind biologic augmentation of tendon-bone healing:
a scientific review,” Instructional course lectures, vol. 63, pp. 443–
450, 2014.
[9] A. M. Abtahi, E. K. Granger, and R. Z. Tashjian, “Factors
affecting healing after arthroscopic rotator cuff repair,” World
Journal of Orthopaedics, vol. 6, no. 2, pp. 211–220, 2015.
[10] P. Randelli, F. Randelli, V. Ragone et al., “Regenerative medicine
in rotator cuff injuries,” BioMed Research International, vol.
2014, Article ID 129515, 9 pages, 2014.
[11] I. G. Petrou, A. Grognuz, N. Hirt-Burri, W. Raffoul, and L. A.
Laurent-Applegate, “Cell therapies for tendons: old cell choice
for modern innovation,” Swiss Medical Weekly, vol. 144, Article
ID w13989, 2014.
[12] R. A. McCormack, M. Shreve, and E. J. Strauss, “Biologic
augmentation in rotator cuff repair—should we do it, who
should get it, and has it worked?”Bulletin of theHospital for Joint
Disease, vol. 72, no. 1, pp. 89–96, 2013.
[13] M. V.Mora,M. A. R. Iba´n, J. D. Heredia et al., “Stem cell therapy
in the management of shoulder rotator cuff disorders,” World
Journal of Stem Cells, vol. 7, no. 4, pp. 691–699, 2015.
[14] Z. Ahmad, F. Henson, J. Wardale, A. Noorani, G. Tytherleigh-
Strong, and N. Rushton, “Review article: regenerative tech-
niques for repair of rotator cuff tears,” Journal of Orthopaedic
Surgery, vol. 21, no. 2, pp. 226–231, 2013.
[15] W. D. Murrell, A. W. Anz, H. Badsha, W. F. Bennett, R. E.
Boykin, and A. I. Caplan, “Regenerative treatments to enhance
orthopedic surgical outcome,” PM&R, vol. 7, no. 4, supplement,
pp. S41–S52, 2015.
[16] M. A. J. Doornaert, H. Declercq, F. Stillaert et al., “Intrinsic
dynamics of the fat graft: in vitro interactions between themain
cell actors,” Plastic and Reconstructive Surgery, vol. 130, no. 5, pp.
1001–1009, 2012.
[17] A. Bedi, T. Maak, C. Walsh et al., “Cytokines in rotator cuff
degeneration and repair,” Journal of Shoulder andElbow Surgery,
vol. 21, no. 2, pp. 218–227, 2012.
[18] N. Pallua, M. Serin, and T. P. Wolter, “Characterisation of
angiogenetic growth factor production in adipose tissue-
derivedmesenchymal cells,” Journal of Plastic Surgery andHand
Surgery, vol. 48, no. 6, pp. 412–416, 2014.
[19] M. Behfar, F. Sarrafzadeh-Rezaei, R. Hobbenaghi, N. Delirezh,
and B. Dalir-Naghadeh, “Adipose-derived stromal vascular
fraction improves tendon healing in rabbits,” Chinese Journal of
Traumatology, vol. 14, no. 6, pp. 329–335, 2011.
[20] A. I. Gonc¸alves,M. T. Rodrigues, S.-J. Lee et al., “Understanding
the role of growth factors in modulating stem cell tenogenesis,”
PLoS ONE, vol. 8, no. 12, Article ID e83734, 2013.
[21] F. Bianchi, M. Maioli, E. Leonardi et al., “A new nonenzymatic
method and device to obtain a fat tissue derivative highly
enriched in pericyte-like elements by mild mechanical forces
from human lipoaspirates,” Cell Transplantation, vol. 22, no. 11,
pp. 2063–2077, 2013.
[22] P. Randelli, E. Conforti, M. Piccoli et al., “Isolation and
characterization of 2 new human rotator cuff and long head
of biceps tendon cells possessing stem cell-like self-renewal
and multipotential differentiation capacity,” American Journal
of Sports Medicine, vol. 41, no. 7, pp. 1653–1664, 2013.
[23] H. Utsunomiya, S. Uchida, I. Sekiya, A. Sakai, K. Moridera,
and T. Nakamura, “Isolation and characterization of human
mesenchymal stem cells derived from shoulder tissues involved
in rotator cuff tears,” American Journal of Sports Medicine, vol.
41, no. 3, pp. 657–668, 2013.
[24] C.-C. Tsai, T.-F.Huang,H.-L.Ma, E.-R.Chiang, and S.-C.Hung,
“Isolation of mesenchymal stem cells from shoulder rotator
cuff: a potential source for muscle and tendon repair,” Cell
Transplantation, vol. 22, no. 3, pp. 413–422, 2013.
[25] N. Song, A. D. Armstrong, F. Li, H. Ouyang, and C. Niyibizi,
“Multipotentmesenchymal stem cells fromhuman subacromial
bursa: potential for cell based tendon tissue engineering,”Tissue
Engineering—Part A, vol. 20, no. 1-2, pp. 239–249, 2014.
[26] A. F. Steinert, M. Kunz, P. Prager et al., “Characterization of
bursa subacromialis-derived mesenchymal stem cells,” Stem
Cell Research &Therapy, vol. 6, p. 114, 2015.
[27] C. Tremolada, G. Palmieri, and C. Ricordi, “Adipocyte trans-
plantation and stem cells: plastic surgery meets regenerative
medicine,” Cell Transplantation, vol. 19, no. 10, pp. 1217–1223,
2010.
Stem Cells International 11
[28] C.-C. Liang, A. Y. Park, and J.-L. Guan, “In vitro scratch
assay: a convenient and inexpensive method for analysis of cell
migration in vitro,” Nature Protocols, vol. 2, no. 2, pp. 329–333,
2007.
[29] A. J. Nixon, L. A. Dahlgren, J. L. Haupt, A. E. Yeager, and D.
L. Ward, “Effect of adipose-derived nucleated cell fractions on
tendon repair in horses with collagenase-induced tendinitis,”
American Journal of Veterinary Research, vol. 69, no. 7, pp. 928–
937, 2008.
[30] N. H. Riordan, T. E. Ichim, W.-P. Min et al., “Non-expanded
adipose stromal vascular fraction cell therapy for multiple
sclerosis,” Journal of Translational Medicine, vol. 7, article 29,
2009.
[31] F. Bacou, R. Boubaker El Andalousi, P.-A. Daussin et al., “Trans-
plantation of adipose tissue-derived stromal cells increases
mass and functional capacity of damaged skeletal muscle,” Cell
Transplantation, vol. 13, no. 2, pp. 103–111, 2004.
[32] K. Rubina, N. Kalinina, A. Efimenko et al., “Adipose stromal
cells stimulate angiogenesis via promoting progenitor cell
differentiation, secretion of angiogenic factors, and enhancing
vessel maturation,” Tissue Engineering Part A, vol. 15, no. 8, pp.
2039–2050, 2009.
[33] F. Bianchi, E. Olivi, M. Baldassarre et al., “Lipogems, a new
modality of fat tissue handling to enhance tissue repair in
chronic hind limb ischemia,” CellR4, vol. 2, no. 6, Article ID
e1289, 2014.
[34] I. Linero and O. Chaparro, “Paracrine effect of mesenchymal
stem cells derived from human adipose tissue in bone regener-
ation,” PLoS ONE, vol. 9, no. 9, Article ID e177001, 2014.
[35] R. J. Griffeth, D. Garc´ıa-Pa´rraga, M. Mellado-Lo´pez et al.,
“Platelet-rich plasma and adipose-derived mesenchymal stem
cells for regenerative medicine-associated treatments in bot-
tlenose dolphins (Tursiops truncatus),” PLoS ONE, vol. 9, no. 9,
Article ID e108439, 2014.
[36] W. Petersen, F. Unterhauser, T. Pufe, T. Zantop, N. Su¨dkamp,
and A. Weiler, “The angiogenic peptide vascular endothelial
growth factor (VEGF) is expressed during the remodeling
of free tendon grafts in sheep,” Archives of Orthopaedic and
Trauma Surgery, vol. 123, no. 4, pp. 168–174, 2003.
[37] W. Petersen, T. Pufe, F. Unterhauser, T. Zantop, R. Mentlein,
and A. Weiler, “The splice variants 120 and 164 of the angio-
genic peptide vascular endothelial cell growth factor (VEGF)
are expressed during Achilles tendon healing,” Archives of
Orthopaedic and Trauma Surgery, vol. 123, no. 9, pp. 475–480,
2003.
[38] M. Bidder, D. A. Towler, R. H. Gelberman, and M. I. Boyer,
“Expression of mRNA for vascular endothelial growth factor
at the repair site of healing canine flexor tendon,” Journal of
Orthopaedic Research, vol. 18, no. 2, pp. 247–252, 2000.
[39] M. I. Boyer, J. T. Watson, J. Lou, P. R. Manske, R. H. Gel-
berman, and S. Rong Cai, “Quantitative variation in vascular
endothelial growth factor mRNA expression during early flexor
tendon healing: an investigation in a canine model,” Journal of
Orthopaedic Research, vol. 19, no. 5, pp. 869–872, 2001.
[40] M. Behfar, F. Sarrafzadeh-Rezaei, R. Hobbenaghi, N. Delirezh,
and B. Dalir-Naghadeh, “Enhanced mechanical properties of
rabbit flexor tendons in response to intratendinous injection of
adipose derived stromal vascular fraction,” Current Stem Cell
Research andTherapy, vol. 7, no. 3, pp. 173–178, 2012.
[41] F. Zhang, H. Liu, F. Stile et al., “Effect of vascular endothelial
growth factor on rat Achilles tendon healing,” Plastic and
Reconstructive Surgery, vol. 112, no. 6, pp. 1613–1619, 2003.
[42] S.M. Perry, S. E.McIlhenny,M.C.Hoffman, and L. J. Soslowsky,
“Inflammatory and angiogenic mRNA levels are altered in
a supraspinatus tendon overuse animal model,” Journal of
Shoulder and Elbow Surgery, vol. 14, no. 1, 2005.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 2014
Zoology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
